Paying for CAR-T Therapy Amidst Limited Health System Resources
Menée dans un contexte américain, cette étude analyse le rapport coût-efficacité d'une immunothérapie à base de lymphocytes CAR-T ciblant CD19 chez des patients adultes atteints d'un lymphome diffus à grandes cellules B réfractaire et/ou récidivant
In the article that accompanies this editorial, Lin et al1 generate evidence around the cost-effectiveness of two recently approved chimeric antigen receptor T-cell (CAR-T) therapies for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The authors used a Markov model to synthesize and extrapolate available cost and benefit evidence to generate cost-effectiveness estimates from the payer perspective and over a lifetime time horizon.1 They conducted extensive sensitivity analyses to account for the uncertainty in the evidence and to present cost-effectiveness evidence under various potential payment agreements.1 They also performed a budget impact analysis to supplement the cost-effectiveness findings with estimates of affordability.1 This work is important and timely, especially for health care payers and patients, because it provides evidence on the long-term value and affordability of resources spent on these innovative, yet extremely costly, CAR-T therapies.(...)
Journal of Clinical Oncology , éditorial en libre accès, 2018